1. Scrip
  2. >>Business
  3. >>Strategy

Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

 
• By Jessica Merrill

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

stairs growth
Novartis laid out a path for growth during an R&D day • Source: Alamy

Novartis AG CEO Vas Narasimhan laid out the company's near- and long-term growth plans to investors, committing to delivering compound annual growth (CAGR) of 4% through 2026 despite the anticipated loss of several top-selling brands to generic competition. The company presented its growth strategy and the key brands and pipeline assets that will drive that growth during a five-hour R&D day on 2 December.

"From 2020 to 2026, the Novartis story is driven by six major brands and then some additional pipeline launches, where we believe we can well overcome the patent expiries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Business

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.